Site-specific positive margins at radical prostatectomy: Assessing cancer-control benefits of wide excision of the neurovascular bundle on a side with cancer on biopsy

BJU International

Volumn 91, Issue 3, 2003, Pages 219-222

  Park, E L ^a   Dalkin, B ^a,b   Escobar, C ^a   Nagle, R B ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b NONE   (United States)

Author keywords

Nerve sparing surgery; Outcome; Prostate cancer; Surgical margins

Indexed keywords

TUMOR MARKER;

ADULT; ANGIOGENESIS; ARTICLE; CANCER CONTROL; CONSERVATIVE TREATMENT; DISEASE COURSE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMALLY INVASIVE SURGERY; NERVE SPARING SURGERY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RISK FACTOR; SURGICAL TECHNIQUE; TRANSRECTAL COLOR DOPPLER ULTRASONOGRAPHY; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT FAILURE; WOUND; WOUND MARGIN;

BIOPSY; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 0037326450     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2003.04071.x     Document Type: Article

References (26)

1. Walsh PC. Anatomic retropubic prostatectomy. In Walsh PC, Retik AB, Vaughan ED, Wein AJ eds, Campbell's Urol, 7th edn. Philadelphia: WB Saunders 1998: 2565
2. Lowe BA, Lieberman SF. Disease recurrence and progression in untreated pathologic stage T3 prostate cancer: selecting the patient for adjuvant therapy. J Urol 1997; 158: 1452-6
3. Watson RB, Civantos F, Soloway MS. Positive surgical margins with radical prostatectomy, detailed pathological analysis and prognosis. Urology 1996; 48: 80-90
4. Obek C, Sadek-S, Lai S, Civantos F, Rubinowicz D, Soloway MS. Positive surgical margins with radical retropubic prostatectomy. Anatomic site-specific pathologic analysis and impact on prognosis. Urology 1999; 54: 682-8
5. Villers A, McNeal JE, Redwine EA, Freiha FS, Stamey TA. The role of perineural space invasion in the local spread of prostatic adenocarcinoma. J Urol 1989; 142: 763-8
6. Rosen MA, Goldstone L, Lapin S, Wheeler T, Scardino PT. Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol 1992; 148: 331-7
7. Sanwick JM, Dalkin BL, Nagle RB. Accuracy of prostate needle biopsy in predicting extracapsular tumor extension at radical retropubic prostatectomy: application in selecting patients for nerve-sparing surgery. Urology 1998; 52: 814-8
8. Partin AW, Borland RN, Epstein JI, Brendler CB. Influence of wide excision of the neurovascular bundle(s) on prognosis in men with clinically localized prostate cancer with established capsular penetration. J Urol 1993; 150: 142-6
9. Dalkin BL, Ahmann FR, Nagle R, Johnson CS. Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer. J Urol 1996; 155: 1357-60
10. Shah O, Melamed J, Lepor H. Analysis of apical soft tissue margins during radical retropubic prostatectomy. J Urol 2001; 165: 1943-8
11. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993; 71: 3582-93
12. Daniels GF Jr, McNeal JE, Stamey TA. Predictive value of contralateral biopsies in unilaterally palpable prostate cancer. J Urol 1992; 147: 870-4
13. Soulie M, Seguin P, Benoit JM et al. Impact of a modified apical dissection during radical retropubic prostatectomy on the occurrence of positive surgical margins: a comparative study in 212 patients. Urology 2001; 58: 217-21
14. D'amico AV, Whittington R, Malkowicz SB et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995; 154: 131-8
15. Stamey TA, Villers AA, McNeal JE, Link PC, Freiha FS. Positive surgical margins at radical prostatectomy, importance of the apical dissection. J Urol 1990; 143: 1166-72
16. Epstein JI, Incidence and significance of positive margins in radical prostatectomy specimens. Urol Clin North Am 1996; 23: 651
17. Jones EC. Resection margin status in radical retropubic prostatectomy specimens, relationship to type of operation, tumor size, tumor grade and local tumor extension. J Urol 1990; 144: 89-93
18. Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 1995; 154: 1818-24
19. Alsikafi NF, Brendler CB. Surgical modifications of radical retropubic prostatectomy to decrease incidence of positive surgical margins. J Urol 1998; 159: 1281-5
20. Vaidya A, Hawke C, Tiguert R, Civantos F, Soloway M. Intraoperative T staging in radical retropubic prostatectomy: is it reliable? Urology 2001; 57: 949-54
21. Voges GE, McNeal JE, Redwine EA, Freiha FS, Stamey TA. Morphologic analysis of surgical margins with positive findings in prostatectomy for adenocarcinoma of the prostate. Cancer 1992; 69: 520-6
22. Blute ML, Bostwick DG, Bergstralh EJ et al. Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy. Urology 1997; 50: 733-9
23. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994; 152: 1837-42
24. Smith RC, Partin AW, Epstein JI, Brendler CB. Extended follow-up of the influence of wide excision of the neurovascular bundle(s) on prognosis in men with clinically localized prostate cancer and extensive capsular perforation. J Urol 1996; 156: 454-8
25. Graefen M, Haese A, Pichlmeier U et al. A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. J Urol 2001; 165: 857-63
26. Huland H, Hubner D, Henke RP. Systematic biopsies and digital rectal examination to identify the nerve-sparing side for radical prostatectomy without risk of positive margin in patients with clinical stage T2, NO prostatic carcinoma. Urol 1994; 44: 211